| Daniel Nermo Brendible, LCSW, CDC1, BHC1 | |
|
563 Brendible Street, Metlakatla, AK 99926 | |
| (907) 886-7491 | |
| (907) 886-4357 |
| Full Name | Daniel Nermo Brendible |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 563 Brendible Street, Metlakatla, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871271536 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 207741 (Alaska) | Primary |
| Entity Name | Metlakatla Indian Community |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740294081 PECOS PAC ID: 5890691315 Enrollment ID: O20031208000361 |
News Archive
RetroVirox, Inc., a biotechnology company specializing in the development of novel antivirals, announced today that it has received a grant award of $296,875 from the National Institute of Allergy and Infectious Disease (NIAID), of the National Institutes of Health (NIH). This is the second award to RetroVirox from the NIH in less than six months. In March 2009 the company received its first grant to develop novel inhibitors of HIV entry.
A good night's sleep is essential for a healthy body and mind, for when we sleep is when the body resets, repairs, and refreshes itself. A lot of people, however, have trouble falling or staying asleep, a condition known as insomnia that affects up to 30% of the population.
Psychological support for those dealing with infertility and its treatment is received by only just half of those who want it in the UK - with many left to suffer with anxiety, depression, or suicidal thoughts, according to a new study published in Human Fertility.
SUNY Downstate scientist Ilham Muslimov, MD, PhD, along with senior author Henri Tiedge, PhD, professor of physiology and pharmacology and of neurology, published a study suggesting that cellular dysregulation associated with certain neurodegenerative disorders may result from molecular competition in neuronal RNA transport pathways.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Nermo Brendible, LCSW, CDC1, BHC1 Po Box 726, Metlakatla, AK 99926-0726 Ph: (907) 617-3146 | Daniel Nermo Brendible, LCSW, CDC1, BHC1 563 Brendible Street, Metlakatla, AK 99926 Ph: (907) 886-7491 |
News Archive
RetroVirox, Inc., a biotechnology company specializing in the development of novel antivirals, announced today that it has received a grant award of $296,875 from the National Institute of Allergy and Infectious Disease (NIAID), of the National Institutes of Health (NIH). This is the second award to RetroVirox from the NIH in less than six months. In March 2009 the company received its first grant to develop novel inhibitors of HIV entry.
A good night's sleep is essential for a healthy body and mind, for when we sleep is when the body resets, repairs, and refreshes itself. A lot of people, however, have trouble falling or staying asleep, a condition known as insomnia that affects up to 30% of the population.
Psychological support for those dealing with infertility and its treatment is received by only just half of those who want it in the UK - with many left to suffer with anxiety, depression, or suicidal thoughts, according to a new study published in Human Fertility.
SUNY Downstate scientist Ilham Muslimov, MD, PhD, along with senior author Henri Tiedge, PhD, professor of physiology and pharmacology and of neurology, published a study suggesting that cellular dysregulation associated with certain neurodegenerative disorders may result from molecular competition in neuronal RNA transport pathways.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.
› Verified 5 days ago
Tiffiney L Mckeehan, L.C.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1271 8th Avenue, Metlakatla, AK 99926 Phone: 907-886-6911 |